Page last updated: 2024-10-31

entinostat and Anemia

entinostat has been researched along with Anemia in 1 studies

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"Addition of entinostat to atezolizumab, carboplatin, and etoposide is unsafe and resulted in early onset and severe neutropenia, thrombocytopenia."5.69Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. ( Bullock, TN; Carducci, MA; Gentzler, RD; Hanley, M; Horton, B; Kim, K; Mock, J; Park, KS; Phelps, MA; Piekarz, R; Rhee, JC; Rudek, MA; Rudin, CM; Villaruz, LC, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gentzler, RD1
Villaruz, LC1
Rhee, JC1
Horton, B1
Mock, J1
Hanley, M1
Kim, K1
Rudek, MA1
Phelps, MA1
Carducci, MA1
Piekarz, R1
Park, KS1
Bullock, TN1
Rudin, CM1

Trials

1 trial available for entinostat and Anemia

ArticleYear
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
    The oncologist, 2023, Nov-02, Volume: 28, Issue:11

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Etoposide; Femal

2023